Galapagos NV ADR (GLPG) - Net Assets
Based on the latest financial reports, Galapagos NV ADR (GLPG) has net assets worth $3.23 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.41 Billion) and total liabilities ($170.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Galapagos NV ADR to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.23 Billion |
| % of Total Assets | 94.99% |
| Annual Growth Rate | 31.45% |
| 5-Year Change | 22.36% |
| 10-Year Change | 326.32% |
| Growth Volatility | 106.37 |
Galapagos NV ADR - Net Assets Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's net assets have evolved over time, based on quarterly financial data. Also explore Galapagos NV ADR assets under control for the complete picture of this company's asset base.
Annual Net Assets for Galapagos NV ADR (2004–2025)
The table below shows the annual net assets of Galapagos NV ADR from 2004 to 2025. For live valuation and market cap data, see GLPG company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.23 Billion | +11.65% |
| 2024-12-31 | $2.90 Billion | +3.63% |
| 2023-12-31 | $2.80 Billion | +10.67% |
| 2022-12-31 | $2.53 Billion | -4.44% |
| 2021-12-31 | $2.64 Billion | -1.01% |
| 2020-12-31 | $2.67 Billion | -7.14% |
| 2019-12-31 | $2.88 Billion | +136.83% |
| 2018-12-31 | $1.21 Billion | +19.99% |
| 2017-12-31 | $1.01 Billion | +33.38% |
| 2016-12-31 | $758.70 Million | +107.86% |
| 2015-12-31 | $365.00 Million | +77.07% |
| 2014-12-31 | $206.13 Million | +23.33% |
| 2013-12-31 | $167.14 Million | +41.11% |
| 2012-12-31 | $118.45 Million | +0.06% |
| 2011-12-31 | $118.38 Million | -20.29% |
| 2010-12-31 | $148.51 Million | +36.40% |
| 2009-12-31 | $108.88 Million | +29.12% |
| 2008-12-31 | $84.32 Million | -14.50% |
| 2007-12-31 | $98.63 Million | -9.97% |
| 2006-12-31 | $109.54 Million | +79.18% |
| 2005-12-31 | $61.14 Million | +489.72% |
| 2004-12-31 | $10.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galapagos NV ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23167737600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $210.49 Million | 6.51% |
| Common Stock | $293.81 Million | 9.08% |
| Other Comprehensive Income | $3.00 Million | 0.09% |
| Other Components | $2.73 Billion | 84.32% |
| Total Equity | $3.23 Billion | 100.00% |
Galapagos NV ADR Competitors by Market Cap
The table below lists competitors of Galapagos NV ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
$1.89 Billion |
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
$1.89 Billion |
|
AUB GROUP LTD.
F:A5H
|
$1.89 Billion |
|
Ivanhoe Electric Inc.
NYSE MKT:IE
|
$1.89 Billion |
|
Tabcorp Holdings Ltd
AU:TAH
|
$1.89 Billion |
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
$1.89 Billion |
|
Intapp Inc
NASDAQ:INTA
|
$1.89 Billion |
|
Autek China Inc
SHE:300595
|
$1.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galapagos NV ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,896,939,000 to 3,234,490,797, a change of 337,551,797 (11.7%).
- Net income of 320,900,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 2,681,723.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $320.90 Million | +9.92% |
| Other Comprehensive Income | $2.68 Million | +0.08% |
| Other Changes | $13.97 Million | +0.43% |
| Total Change | $- | 11.65% |
Book Value vs Market Value Analysis
This analysis compares Galapagos NV ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 16.43x to 0.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $1.75 | $28.68 | x |
| 2005-12-31 | $6.84 | $28.68 | x |
| 2006-12-31 | $8.09 | $28.68 | x |
| 2007-12-31 | $4.77 | $28.68 | x |
| 2008-12-31 | $3.98 | $28.68 | x |
| 2009-12-31 | $5.03 | $28.68 | x |
| 2010-12-31 | $6.12 | $28.68 | x |
| 2011-12-31 | $4.48 | $28.68 | x |
| 2012-12-31 | $4.46 | $28.68 | x |
| 2013-12-31 | $5.81 | $28.68 | x |
| 2014-12-31 | $6.85 | $28.68 | x |
| 2015-12-31 | $10.22 | $28.68 | x |
| 2016-12-31 | $16.60 | $28.68 | x |
| 2017-12-31 | $20.45 | $28.68 | x |
| 2018-12-31 | $23.30 | $28.68 | x |
| 2019-12-31 | $49.91 | $28.68 | x |
| 2020-12-31 | $41.04 | $28.68 | x |
| 2021-12-31 | $40.36 | $28.68 | x |
| 2022-12-31 | $38.45 | $28.68 | x |
| 2023-12-31 | $42.40 | $28.68 | x |
| 2024-12-31 | $43.80 | $28.68 | x |
| 2025-12-31 | $49.09 | $28.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galapagos NV ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.92%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.85%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.05x
- Recent ROE (9.92%) is above the historical average (-6.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -34.62% | -46.15% | 0.50x | 1.51x | $-4.63 Million |
| 2005 | -10.70% | -58.19% | 0.14x | 1.33x | $-12.65 Million |
| 2006 | -10.35% | -32.25% | 0.21x | 1.53x | $-22.29 Million |
| 2007 | -22.25% | -33.29% | 0.44x | 1.51x | $-31.81 Million |
| 2008 | -17.30% | -18.95% | 0.65x | 1.41x | $-23.02 Million |
| 2009 | 2.76% | 3.23% | 0.65x | 1.32x | $-7.88 Million |
| 2010 | 2.94% | 3.57% | 0.63x | 1.31x | $-10.48 Million |
| 2011 | -27.96% | -34.52% | 0.60x | 1.36x | $-44.93 Million |
| 2012 | -4.83% | -4.20% | 0.58x | 1.99x | $-17.57 Million |
| 2013 | -4.83% | -5.87% | 0.48x | 1.72x | $-24.79 Million |
| 2014 | 16.11% | 47.88% | 0.26x | 1.31x | $12.60 Million |
| 2015 | -32.44% | -299.29% | 0.09x | 1.21x | $-154.91 Million |
| 2016 | 7.12% | 41.70% | 0.12x | 1.43x | $-21.86 Million |
| 2017 | -11.43% | -91.04% | 0.10x | 1.27x | $-216.90 Million |
| 2018 | -2.41% | -10.13% | 0.20x | 1.19x | $-150.68 Million |
| 2019 | 5.21% | 17.95% | 0.14x | 2.11x | $-137.72 Million |
| 2020 | -11.44% | -63.89% | 0.08x | 2.14x | $-572.47 Million |
| 2021 | -4.74% | -25.87% | 0.09x | 1.96x | $-389.76 Million |
| 2022 | -8.63% | -90.36% | 0.05x | 1.87x | $-470.59 Million |
| 2023 | 7.57% | 88.31% | 0.06x | 1.56x | $-67.86 Million |
| 2024 | 2.56% | 26.88% | 0.07x | 1.43x | $-215.61 Million |
| 2025 | 9.92% | 28.85% | 0.33x | 1.05x | $-2.55 Million |
Industry Comparison
This section compares Galapagos NV ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galapagos NV ADR (GLPG) | $3.23 Billion | -34.62% | 0.05x | $1.89 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more